Healthcare stocks may struggle to gain sustained momentum in the near term as Democrats prepare to take over Congress, according to industry analysts examining the evolving political landscape and its potential ramifications for the broader medical sector.
Speaking on CNBC’s "Fast Money," Jared Holz, who covers healthcare for Mizuho, pointed out that the outlook for the sector remains clouded by uncertainty, largely driven by the prospect of legislative gridlock between lawmakers in Washington. As the balance of power shifts on Capitol Hill, investors are weighing how divided or shifting governance might stall major policy changes, impacting everything from major pharmaceutical companies to medical device manufacturers.
"The next couple of years I really can’t see too much happening," Holz told CNBC on Wednesday, highlighting the anticipated legislative stalemate. "I’m not sure you want to own everything, but you can pick and choose the names… Pharma is trading more expensive than tech for the first time in 20 years. So, I backed away from pharma. I would look at medtech."
The cautious sentiment comes on the heels of notable market movements earlier in the week. The State Street Health Care Select ETF (XLV) experienced a sharp 3% jump just a day after Election Day, catching some market watchers by surprise given the complex web of political and economic variables influencing equities.
"You had this very weird situation where typically you wouldn’t have all of these categories work in tandem, and they did. So, I think some things just a little bit off," Holz said, offering his perspective just a day before the broader healthcare sector became swept up in a wider Wall Street sell-off on Thursday.

While the immediate horizon appears choppy, Holz outlined potential future catalysts that could breathe new life into the sector. According to the Mizuho healthcare specialist, healthcare’s real booster shot may arrive further down the road, specifically if a Democrat manages to win the White House in the 2028 presidential election.
"Then I think you see some of the Trump strategies rolled back. That’s where I think healthcare could actually perform well," Holz said. He noted, however, that such a rally would heavily hinge on Democrats managing to retain control of both the Senate and the House of Representatives, maintaining a unified legislative front to implement policy shifts.
For investors maintaining a long position in healthcare, Holz emphasized that the sector should not be treated as a monolithic block. Instead, market participants need to evaluate each subsector through a distinct lens, considering the unique regulatory pressures, valuations, and macroeconomic tailwinds or headwinds facing different segments of the industry.
When evaluating the possibility of regulatory relief, Holz remained realistic about the timeline for undoing recent policy measures.
"Can we get some of the regulation that has taken place over the past couple of years and overturn that over the near term? I don’t necessarily believe so," Holz said. "Pero if you do, then you probably want to be long some of these medical device stocks that are at or near multi-year lows."
The State Street Health Care Select ETF ultimately ended the week virtually flat, reflecting the tug-of-war between optimistic sector positioning and broader market volatility. Despite the recent turbulence, the ETF has demonstrated considerable resilience over a broader timeframe, boasting an increase of around 32% since President Trump took office in January 2025. That performance has outpaced the broader S&P 500 index by almost 9 percentage points, highlighting the underlying strength and defensive appeal that certain healthcare segments have offered investors navigating a shifting political and economic landscape.

Comments (0)